Financials
Financial year 2025
NEOGEN from Anderlecht, company number BE0445922856, closed financial year 2025 with a result of € 2.4 million after tax. For that financial year NEOGEN recorded a gross margin of € 2.1 million and equity of € 14.1 million. Compared with financial year 2024, the result moved from € 3 million to € 2.4 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 27, 2026.
€ 14.1 million
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.4 million
▼ 21% vs 2024
Profit after tax over the fiscal year.
€ 31,419
▼ 35% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.7 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1.1 million
▲ 224% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,801,418 | € 2,798,557 | € 2,779,710 | € 2,092,937 | ▼ 25% |
| Profit after taxes | € 939,744 | € 2,851,128 | € 3,018,440 | € 2,391,417 | ▼ 21% |
| Equity | € 5,813,444 | € 8,664,572 | € 11,683,012 | € 14,074,430 | ▲ 20% |
| Total debts | € 5,288,489 | € 4,436,921 | € 3,511,082 | € 3,676,940 | ▲ 5% |
| Cash | € 103,875 | € 64,484 | € 48,607 | € 31,419 | ▼ 35% |
| Retained profit | € -6,579,156 | € -3,728,028 | € -709,588 | € 1,681,830 | ▲ € 2.4 million |
| Balance sheet total | € 11,101,933 | € 13,101,493 | € 15,194,094 | € 17,751,370 | ▲ 17% |
Key figures of NEOGEN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NEOGEN?
What happened at NEOGEN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Cellular Consulting BO stepped down as director. NBB
- LMDC Advisory s.r.o. BO stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.4 million (▼ 21% vs 2024). filed late Source: NBB ↗
- LMDC Advisory s.r.o. BO became a director. NBB
- LMDC GmbH BO stepped down as director. NBB
- Cellular Consulting BO became a director. NBB
- LMDC GmbH BO became a director. NBB
- New establishment in Anderlecht. KBO
In short
From € 939,744 profit in 2022 to € 2.4 million profit in 2025.
Best year ever: 2024, with € 3 million profit.
Management
The stake of A.forall Development comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
NEOGENThe shares are held by A.forall Development (100%).
Directors
According to the 2025 annual accounts
since 2024 · until 2025
Director · represented by Bruno Febra
since 2025 · until 2031
LMDC Advisory s.r.o. BO
Managing director · represented by Libor Matyasek
Also active at: A.forall Development
since 2026 · until 2031
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Marie Curiesquare 50
1070 Anderlecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0445.922.856
- VAT number
- BE 0445.922.856
- Registered office
- Marie Curiesquare 50, 1070 Anderlecht
- Names & denominations
- NEOGEN
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 December 1991
- Peppol
- Active · Active since 6 Jan 2026
- Activities · NACE
Vervaardiging van geneesmiddelen